Skip to main content

Coherus Oncology, Inc 8-K, filed Feb 4, 2020

Coherus Oncology, Inc. (CHRS)

8-K 2020-02-04 For: 2020-02-03
View Original
Added on April 09, 2026

About this 8-K

Coherus Oncology, Inc filed this 8-K on February 4, 2020, reporting on events of February 3, 2020.

Items reported

  • Item 8.01: Other events

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENTREPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 3, 2020

COHERUS BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware 001-36721 27-3615821
(State or other jurisdictionof incorporation) (CommissionFile Number) (IRS EmployerIdentification Number)

333 Twin Dolphin Drive, Suite 600

Redwood City, CA 94065

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (650) 649-3530

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17<br>CFR 240.14a-12)
--- ---
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
--- ---
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
--- ---

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading<br><br><br>Symbol(s) Name of each exchange<br><br><br>on which registered
Common Stock, $0.0001 par value per share CHRS The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

As previously disclosed, Coherus BioSciences, Inc. (the “Company”) licensed U.S. rights from Bioeq AG (“Bioeq”) to Bioeq’s Lucentis^®^ (ranibizumab) biosimilar candidate. Bioeq filed a Biologic Licensing Application (“BLA”) with the U.S. Food and Drug Administration (“FDA”) in December 2019.

At the request of a national European health authority addressed to Bioeq’s drug substance contract manufacturer, the manufacturer moved a piece of processing equipment to a different location within the same site after the production of Bioeq’s Lucentis^®^ (ranibizumab) biosimilar candidate qualification batches was completed.

The FDA has requested additional manufacturing data for the equipment in its new location in the context of its review of the BLA application. The Company believes that it will take approximately four months to generate this additional data to comply with the FDA’s request. As a result, Bioeq has decided to withdraw its BLA application for its Lucentis^®^ (ranibizumab) biosimilar candidate, provide the requested data and resubmit the application thereafter. The Company anticipates that such withdrawal and resubmission may delay the approval of a BLA for Bioeq’s Lucentis^®^ (ranibizumab) biosimilar candidate.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 4, 2020 COHERUS BIOSCIENCES, INC.
By: /s/ Jean-Frédéric Viret
Name: Jean-Frédéric Viret
Title: Chief Financial Officer